.png){kind=icon}
.png){kind=icon}
Return
Effectiveness and safety of mirikizumab in multirefractory ulcerative colitis: analysis from a real-world cohort
.png){kind=icon}
OA
AI
L
O
N
V
V
M
M
H
P
F
DOI：10.1016/j.dld.2026.06.007.png)
.png){kind=icon}
.png){kind=icon}
Share.png){kind=icon}
Save
Abstract
En 中文
Mirikizumab is a selective anti-IL-23 monoclonal antibody approved for moderate-to-severe ulcerative colitis (UC). Evidence regarding its efficacy mostly derives from registration trials, as real-world data in multi-refractory populations remain limited.
Keywords:
Ulcerative colitis
Multirefractory
Mirikizumab
Real-world
AI Summary
Key information extracted from the uploaded paper, including a brief overview, abstract, background, key highlights, visual analysis, and future outlook.
Journal
IF:
3.8
Papers:
1.2W
Citations:
8.7K
Organization
Cited Papers